Moffitt Cancer Center | Strategic Alliance Partners

November 16, 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

October 17, 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

October 02, 2019

Rutika Mehta, MD, MPH, discusses a phase II trial that will combine ramucirumab with TAS-102 in patients with advanced gastric and gastroesophageal junction cancer.

October 01, 2019

Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.

September 25, 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

September 24, 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses recent progress that has been made in advanced gastric cancer.

September 21, 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

September 11, 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

September 04, 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

August 05, 2019

Mian M. Shahzad, MD, PhD, discusses the use of checkpoint inhibition in advanced ovarian cancer.

August 05, 2019

Jeannie Chern, MD, discusses developments with genetic testing in ovarian cancer and key trials in patients with recurrent disease.

August 02, 2019

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

August 01, 2019

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

July 30, 2019

Robert M. Wenham, MD, discusses frontline management strategies for patients with newly diagnosed advanced ovarian cancer as well as the complexities of maintenance therapy.

July 25, 2019

Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

July 09, 2019

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

June 26, 2019

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.

June 19, 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).

April 26, 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

April 23, 2019

Bijal D. Shah, MD, oncologist/hematologist, Moffitt Cancer Center, discusses ongoing trials in the field of mantle cell lymphoma (MCL).